

## Special Issue

# When Vaccinations are Challenging: From Immune Diseases to Hypersensitivity Reactions

### Message from the Guest Editor

Although vaccines have been part of physicians' practice for many years and represent the most successful prevention strategy for communicable diseases, some challenges still characterize their daily use and applicability. In fact, vaccines have been recently proposed as part of the management of some peculiar conditions, such as immune diseases, particularly immunodeficiency, chronic respiratory diseases or bronchiectasis, and autoimmune diseases treated with immunosuppressant drugs. The expected outcomes, as well as their use in specific phenotypes, have not been completely clarified. Further, risk assessment, prevention, and management of hypersensitivity reactions to vaccines still present some controversial aspects. This *Vaccines* Special Issue aims at addressing the above-mentioned challenges and unmet needs through reviews and research contributions, including original articles and case series/reports.

### Guest Editor

Dr. Marco Caminati

Department of Medicine, University of Verona, Verona University Hospital, 37134 Verona, Italy

### Deadline for manuscript submissions

closed (31 May 2021)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/41394](https://mdpi.com/si/41394)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).